三阴性乳腺癌组织胞外HSP90α表达与新辅助化疗预后关系  

Significance prognosis of extracellular HSP90α for neoadjuvant chemotherapy in triple negative breast cancer

作　　者：单宏杰[1] 谢芳[1] 肖迎利 马骖[1] SHAN Hong-jie;XIE Fang;XIAO Ying-li;MA Can(Department of Oncology Surgery,Suzhou Hospital Affiliated to Anhui Medical University,Suzhou 234000,P.R.China)

机构地区：[1]安徽医科大学附属宿州医院肿瘤外科,安徽宿州234000

出　　处：《中华肿瘤防治杂志》2020年第4期293-297,共5页Chinese Journal of Cancer Prevention and Treatment

基　　金：安徽医科大学附属宿州医院院级课题(2015A039)。

摘　　要：目的胞外热休克蛋白90α(heat shock protein,HSP90α)是细胞分化的重要伴侣蛋白,在肿瘤复发和转移中具有重要作用。本研究探讨胞外HSP90α在三阴性乳腺癌新辅助化疗评估中的作用。方法回顾性分析安徽医科大学附属宿州医院肿瘤外科2013-01-13-2018-07-16收治的140例三阴性乳腺癌临床资料,其中观察组(70例)行新辅助化疗,所有患者均采用ET(表柔比星75mg/m^2+多西他赛75mg/m^2)方案6个周期,观察其治疗效果并随访复发情况,分析三阴性乳腺癌治疗及其生存影响因素。对照组(70例)常规治疗。入院后2组患者采用酶联免疫吸附试验(enzymelinked immunosorbent assay,ELISA)检测胞外HSP90α。结果治疗前观察组胞外HSP90α表达〔42.86%(30/70)〕高于对照组〔8.75%(8/70)〕,Z=-4.016,P<0.001。治疗后观察组胞外HSP90α表达〔7.14%(5/70)〕低于对照组〔8.57%(6/70)〕,差异有统计学意义,Z=-2.134,P=0.033。胞外HSP90α高、低表达组新辅助治疗结果比较,差异有统计学意义,χ^2=6.392,P=0.011。新辅助治疗临床完全缓解组无病生存期(59个月)长于非临床完全缓解组(48个月),χ^2=8.63,P<0.01。新辅助治疗临床完全缓解是三阴性乳腺癌独立预后因素,HR=8.140,P<0.001。结论胞外HSP90α表达与三阴性乳腺癌新辅助化疗预后具有统计学意义的关联。OBJECTIVE To explore the role of extracellular heat shock protein(HSP90α)for the efficacy of neoadjuvant chemotherapy in triple negative breast cancer.METHODS A total of 140 patients with breast cancer who had surgical rescetion from 2013-01-13 to 2018-07-16 in Suzhou Hospital Affiliated to Anhui Medical University were collected and retrospectively analyzed.The observation group(70 cases)was the neoadjuvant chemotherapy triple-negative breast cancer,and the control group(70 cases)was the non-neoadjuvant chemotherapy triple-negative breast cancer.Extracellular HSP90 awas detected by enzyme-linked immunosorbent assay(ELISA).Neoadjuvant chemotherapy was performed on patients of the observation group and all triple-negative breast cancer patients received six courses of ET(epirubicin75 mg/m2+docetaxel 75 mg/m2).The therapeutic effect and the recurrence was observed.The influencing factors of treatment and survival of triple negative breast cancer were analyzed.RESULTS Pre-treatment,the expression of extracellular HSP90αin the observation group was[42.86%(30/70)]higher than that[8.75%(7/70)]in the control group(Z=-4.016,P<0.01).Post-treatment,the expression of extracellular HSP90αin the observation group was[7.14%(5/70)]lower than that[8.57%(6/70)]in the control group(Z=-2.134,P=0.033).The difference was statistically significant.Compared with the results of neoadjuvant therapy,the expression of extracellular HSP90 alpha wasχ~2=6.392,P=0.011.The difference was significant.The disease-free survival time of neoadjuvant therapy group was longer than that of non-clinical complete remission group(χ^2=8.63,P<0.01).Complete remission of neoadjuvant therapy was an independent prognostic factor for triple negative breast cancer(HR=8.140,P=0.004).CONCLUSION Extracellular HSP90αis significantly correlated with the prognosis of neoadjuvant chemotherapy in triple negative breast cancer.

关 键 词：胞外HSP90α 三阴性乳腺癌 新辅助化疗 预后 酶联免疫吸附试验 

分 类 号：R737.9[医药卫生—肿瘤]